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Introduction
Diabetic retinopathy (DR) is the most common microvascular 
complication of diabetes. DR affects 8.2% of the Irish popula-
tion over 50 years with type 2 diabetes1 and is the leading causes 
of blindness among adults of working age2. Regular diabetic 
retinopathy screening (DRS) leads to the earlier detection of 
retinopathy and treatment that can prevent or delay the develop-
ment of diabetes-related blindness. Although DRS is found to 
be effective, few countries have established a population-based 
DRS programme. In 2013, the new national programme (Diabetic 
RetinaScreen) was introduced in Ireland offering free, regular 
retinopathy screening to people with diabetes.
Ensuring a high uptake of retinopathy screening is challenging3. 
Prior to the introduction of a national programme, there 
was variation in attendance at regional screening services in Ire-
land, with attendance rates ranging from 49–80%4–6. Screen-
ing uptake has also been identified as a challenge in countries 
such as the UK; with attendance rates ranging from 56–90%7. 
Non-attendance at screening has been identified as a risk fac-
tor for poor visual outcomes among those with diabetes8. Factors 
associated with non-attendance include, younger age9,10, type 1 
diabetes9, poor glycaemic control9,11 and lack of awareness of 
the benefits of DRS or the risk of DR among patients6,12. A rec-
ommendation from a healthcare provider6,12 and fear of impaired 
vision12 have been shown to motivate attendance. Little is 
known about characteristics which determine the uptake of reti-
nal screening among those with diabetes in the Irish context4,6. 
The aim of this study was to identify factors associated with 
participation in a new national retinopathy screening service using 
data from primary care.
Methods
National Screening Programme
RetinaScreen is a government-funded programme providing 
free, annual retinal screening, and, if necessary, treatment, to 
anyone aged 12 years or older with diagnosed diabetes. The 
programme was commissioned in 2011 and rolled out in 2013 
and 201413. The current study was conducted during the ini-
tial phase of the programme (2013–2015). In Ireland, there is no 
national register of people with diabetes. The programme reg-
ister was populated in 2012 using information from existing 
national health schemes, specifically pharmacy claims data. GPs 
or by other healthcare professionals involved in diabetes care 
can add also add patients to the register by directly contacting 
RetinaScreen. All those on the register are invited by letter to par-
ticipate in the programme13, after which they provide consent for 
the programme to hold and use their contact details and receive 
an appointment. Once consented they receive an appointment, 
after which they need to attend. Figure 1 illustrates this process 
of registration, consenting to and attending the programme. To 
receive an appointment, people first need to consent to the pro-
gramme. Once consented they receive an appointment, after 
which they need to attend.
Population
Members of the target population were people with diabetes 
aged 18 years and over who were eligible to participate in 
Figure 1. Flow diagram illustrating process of consenting and attending to the programme. HCP; Health Care Professional.
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RetinaScreen during the uptake period of interest, that is, diag-
nosed with diabetes four months before the end of the uptake 
period of interest (Practice A: between July 2014 and August 
2015; Practice B between November 2013 and December 2014).
Research setting
Data collection was carried out across two large primary 
healthcare centres (Practice A and Practice B) located in two 
different Community Health Organisations in Ireland (Figure 2). 
Practice A had seven GPs with five practice nurses and approxi-
mately 22,000 patients. Practice B had eight GPs with four 
practice nurses and approximately 20,000 patients.
Data collection
The two primary care centres used the same computerised 
IT system, therefore data collection methods described were car-
ried out across both sites. All adults aged ≥18 years with diabetes 
were identified via the practice database, using the Interna-
tional Classification of Primary Care, Second Edition (ICPC-2) 
codes for diabetes insulin dependent (T89) and diabetes non-
insulin dependent (T90). Duplicates were removed and data were 
extracted from each individual medical record. Next, the follow-
ing inclusion criteria were applied: age 18 years and older, com-
munity-dwelling, diagnosed with diabetes at least four months 
before the end of the uptake period of interest (Practice A: before 
May 2015; Practice B: before September 2014). Exclusion 
criteria were, a diagnosis of prediabetes or gestational diabetes 
or diabetes insipidus, no perception of light in both eyes (blind-
ness) as documented in medical records, nursing home residence, 
visiting patient to the practice.
Data were extracted from eligible individual’s medical record. 
Each medical record was checked for a RetinaScreen letter 
(results letter or did not attend letter). RetinaScreen was contacted 
to establish the status of those who did not have a letter on 
file. Individuals were then categorised into four groups:
1. Not registered (details were not listed on the 
RetinaScreen database),
2. Non-consenters (details were listed in the RetinaScreen 
database but did not respond to the RetinaScreen 
initial letter asking for individual’s consent to hold and 
use their contact details),
3. Non-attenders (details were listed on the RetinaScreen 
database; they responded to the RetinaScreen invitation 
letter but did not attend screening appointment)
4. Attenders (details were listed on the RetinaScreen 
database, responded to the RetinaScreen invitation 
letter and attended appointment).
In each practice, the beginning of the uptake period was defined 
as the earliest date of the first screening results letter available 
on file (Figure 2). The end of the uptake period was defined as 
the last day of data collection; hence the uptake period for each 
practice was 14 months in duration. 
Individual-level characteristics were also extracted from the 
patient’s medical records and included: date of birth, gender, 
healthcare cover (medical card/private insurance), diabetes type 
(type 1/type 2), date of GP diabetes diagnosis (≤2012 vs. >2012) 
and a previous doctor diagnosis of hypertension. A previous 
diagnosis of myocardial infarction, congestive cardiac failure, 
cerebrovascular accident and transient ischaemic attack were 
defined as macrovascular complications. A previous diagnosis of 
DR, diabetic neuropathy or diabetic nephropathy were defined as 
microvascular complications. Each medical record was checked 
Figure 2. Timeline of the national programme, RetinaScreen, and data collection at study sites.
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for a results letter from existing retinopathy screening serv-
ices; attendance at existing retinopathy screening services (for 
example a private ophthalmologist or previous regional initia-
tive) was categorised into two groups: no evidence of attending 
existing retinopathy screening services (‘none’) and evidence of 
attending existing retinopathy screening services (‘previous attend-
ance’). Age (years) was calculated by subtracting year of birth 
from year of uptake period and was categorised into three age 
groups (18–39 years; 40–65 years; 65 years and over). Duration 
of diabetes diagnosis was calculated by subtracting year of GP 
diabetes diagnosis from year of uptake period and was categorised 
into three groups (0–4 years; 5–9 years; 10 years and over).
Data analysis
Analysis was carried out in Stata version 13 for windows 
(StataCorp, College Station, TX). Descriptive statistics were 
used to summarise characteristics of patients and were stratified 
according to outcome group. Uptake was calculated as the number 
of people who participated in the programme (consented and 
attended) and reported as a proportion of the total who were reg-
istered. Group specific differences in categorical variables were 
analysed using Pearson’s chi-square test. The mean and stand-
ard deviation were reported if continuous data conformed to 
normality and the student t-test was conducted to compare mean 
differences. If data were skewed, the median with associated 
lower and upper quartile values was reported and the Kruskal 
Wallis test was utilised. Associations between predictor vari-
ables and programme outcomes were examined with multivariable 
Poisson regression. Adjusted incident rate ratios (IRR) with 
95% CI were generated as a measure of association. Predictor 
variables were selected based on whether they had been reported 
in the literature as significant predictors of uptake to diabetic 
retinopathy screening.
Ethical considerations
Ethical approval for the study was obtained from the Clini-
cal Research Ethics Committee for the Cork Teaching Hospitals 
(ECM 4 (o)). Patient consent for the use of their medical records 
was waived by the ethics committee as no patient records or 
identifiable data were removed from primary care centres. MT 
acted as a ‘Data processor’ on behalf of the general practitioner 
and a ‘Data Protection and Confidentiality Agreement’ was signed 
by the general practitioner and MT.
Results
Uptake of Diabetic RetinaScreen
A total of 722 people with type 1 and type 2 diabetes were 
identified during data collection (Figure 3). At the time of data 
collection, one fifth of patients (n = 141) were not registered 
with RetinaScreen. A total of 582 people were registered and 
had been invited to participate in the screening programme. 
Of these, 66% consented to take part (n = 382), the majority of 
whom attended screening. Overall, 63% of those who were 
registered (n = 365), participated; i.e., consented and attended 
(Figure 3).
Most of the 217 who had not participated in the programme 
had not consented for the programme to hold and use their 
details (n = 200, 92%). While the uptake of RetinaScreen was 
63% among those who were registered for the programme 
(n = 365/582), only half (n = 365/722) of the eligible popula-
tion of people with diabetes had participated in the new national 
programme at the time of the study.
Characteristics of the target population
The characteristics of the 582 people who were registered 
with RetinaScreen are shown in Table 1. The mean age of 
Figure 3. Outcome status of individuals identified during data collection. *Registered, details listed on the screening programme database; 
invitation letter to avail of screening sent. **Not registered, details not listed on the screening programme database. ║Not consenting, did not 
response to invitation letters; ¶Attending, attended screening appointment. §Not attending, responded to invitation letter but did not attend 
screening appointment.
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patients was 63.0 years (SD 13.8), 61% were male and 91% had 
type 2 diabetes. Approximately half of the sample had evidence 
of attending existing retinopathy screening services in their 
medical record (52%).
Predictors of consenting to Diabetic RetinaScreen
Most people who consented to participate in the programme 
subsequently attended (n = 365/382, 95.6%). Therefore, consent 
to be invited to participate was the outcome of interest for the 
regression analysis. Table 2 presents the results from the Pois-
son regression analyses. Multivariable analysis indicated that 
people who had previously attended an existing retinopathy 
screening service (IRR = 0.65 [95% CI 0.5-0.8]; p<0.001) were 
less likely to consent.
Discussion
This study outlines uptake of DRS among people with diabetes 
in Ireland during the initial implementation of a new national 
screening programme. Over the 14-month period the overall 
uptake (consenting and attending) among people who were 
registered was 63%. This is similar to the most recent figures 
(61%) available from RetinaScreen; i.e., people sent a consent let-
ter who attended14, and higher than previously reported in some 
regional community-based screening initiatives15–17. Consent 
was the outcome of interest as this is the first point of engage-
ment with the programme before a patient can attend screen-
ing. Encouragingly, once consented, most people attended their 
screening appointment.
National figures indicate that, in the first round of screening 
(March 2013 to December 2014), of the 134,513 people who were 
invited to participate (sent a consent letter), 57.1% consented 
to RetinaScreen13. This is lower than the proportion of people 
reported in the current study (66%). While previous studies have 
found factors such as age9,10, type of diabetes and duration9 to 
be associated with DRS uptake, our analysis only found that 
previous attendance to an existing retinopathy screening service 
significantly predicted consenting to take part in the pro-
gramme. This suggests that people who already are aware of, and 
familiar with, DRS are more inclined to attend the new national 
programme. A lack of awareness of DR and the risk has previ-
ously been reported as a barrier to attendance6,12,18,19. An Irish 
study conducted in 2015 which surveyed patients attending gen-
eral practices and diabetes outpatient clinics about screening 
behaviours, reported 91% had never previously heard of 
RetinaScreen20. However, since then the programme has introduced 
further advertising and may be more familiar to patients.
We found one fifth of patients were not registered with Reti-
naScreen at the time of the study. The introduction of the 
Cycle of Care, in 2015, may improve RetinaScreen registra-
tion rates for those with a medical card as it provides financial 
remuneration to General Practitioners (GPs) for providing struc-
tured care for people with type 2 diabetes who have a medi-
cal card. The structured review visit includes monitoring of key 
processes of care including screening attendance. In this study, 
34% of those not registered would not be eligible for the Cycle 













N (%) N (%) N (%) N (%)
Demographics 
Age years (mean, SD)
63.0 (13.8) 63.8 (12.8) 57.9 (17.6) 62.1 (15.1)
Gender [Male] 355 (61) 227 (62) 6 (35) 122 (61)
Medical card 406 (70) 252 (69) 12 (71) 142 (71)
Diabetes
Type 2 531 (91) 341 (93) 14 (82) 176 (88)
Year of diagnosis ≤2012 533 (92) 337 (92) 14 (82) 182 (91)




























*Evidence of retinopathy screening at existing screening provider in medical record
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of Care. Systems should be put in place to support profession-
als to register and encourage attendance among all patients. 
With routine management of type 2 diabetes taking place in 
the community, primary care professionals are well positioned 
to promote DRS attendance. A recommendation to attend screen-
ing from a primary care professional has been found to motivate 
attendance18,19,21. In a survey of GPs in Ireland, 56% identified 
the time required to register patients as a barrier20. Since this 
study, RetinaScreen have introduced a number of measures to 
facilitate registration and consent, including an online refer-
ral system (2015), and a single step registration and consent 
form which can be returned by patients directly to RetinaScreen 
(2019). It is important to recognise that service innovations evolve 
as they become more embedded in everyday practice. As such, 
with new implementation strategies Retinascreen may have 
addressed initial challenges and reasons for non-participation 
may change over time.
It is important to acknowledge the limitations of this study. 
First, as mentioned, the study was undertaken during the initial 
phase of an on-going implementation process. However, esti-
mates from the current study are in line with more recent figures 
from the programme. Patients may be attending private pro-
viders, and we cannot assess this using the current data. 
Quantitative data were extracted using a standardised extraction 
template and relevant quality checks were applied to the data. 
We acknowledge that the completeness and accuracy of our 
study is dependent on the consistency and timely application of 
codes in each practice. However, both practices have systems in 
place to ensure that databases are maintained to a high standard. 
The type of predictors examined by this study are limited to those 
available in patient records. Other factors found to be impor-
tant in previous studies, for example, socio economic status 
(SES)22–25, self-management, and history of glycaemic control18, 
could not be included.
Conclusion
We found over one third of people eligible to participate in 
the free national retinal screening programme, Diabetic Reti-
naScreen, had not done so. The results suggest DRS attendance 
could be supported by raising awareness of screening and 
supporting professionals to register and encourage their patients 
to attend. Type 2 diabetes, which accounts for about 90% of all 
cases of diabetes26, is largely managed in primary care, mak-
ing this a suitable setting in which to introduce strategies to 
support DRS uptake. Further research is needed to better 
understand barriers and enablers of DRS uptake in the Irish 
context, and to determine strategies would effectively target these 
Table 2. Contextual predictors of consenting to RetinaScreen.
Variables
Crude 
IRR (95% CI) 
(n=582) p
Adjusted1 














































































































1variables entered into model: age, gender, healthcare cover, diabetes type, years since diagnosis, screening history
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factors. In Ireland, the population eligible for screening is 
increasing each year27, therefore implementing effective strategies 
to maximise uptake of DRS must be a priority from the outset.
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